Female CEOs
Health
Pharmaceutical

Editas Medicine

$21.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.54 (2.55%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EDIT and other stocks, options, ETFs, and crypto commission-free!

About

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). Read More The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.

Employees
133
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
1.06B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
866.50K
High Today
$21.82
Low Today
$21.26
Open Price
$21.30
Volume
161.55K
52 Week High
$41.43
52 Week Low
$17.80

Collections

Female CEOs
Health
Pharmaceutical
Therapy
Medical
Technology
Biotechnology
2016 IPO

News

Yahoo FinanceMay 19

Edited Transcript of EDIT earnings conference call or presentation 7-May-19 9:00pm GMT

Q1 2019 Editas Medicine Inc Earnings Call Cambridge May 20, 2019 (Thomson StreetEvents) -- Edited Transcript of Editas Medicine Inc earnings conference call or presentation Tuesday, May 7, 2019 at 9:00:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Charles Albright Editas Medicine, Inc. - Chi...

227
Seeking AlphaMay 14

May Outlook On Editas Medicine

Without more clinical news, analysis shows an opportunity for a short-term bump upward until it hits resistance points again. Stock prices have traded without much more news inside resistance near the $27 and support just under $20. Editas has seen bounce back from concerns in 2018 of its portfolio, and gained on news of its EDIT-101 clinicals. Editas (EDIT) has resumed the uptrend after a bearish pullback to the 78.6% Fibonacci retracement price of $19.82. Price is now at the 61.8% Fibonacci retracement...

871
The Motley FoolMay 8

Editas Gears Up for a Busy 2019

Editas Medicine (NASDAQ:EDIT) released first-quarter 2019 results on Tuesday after the market closed. The genome-editing leader highlighted the continued march of its primary EDIT-101 drug candidate, for treating Leber congenital amaurosis type 10 (LCA10), toward a historic dose-escalation study later this year; progress on its earlier stage medicine-development initiatives; and a promising new partnership to further extend its reach. With shares down up around 2% on Wednesday in response, let's have a clo...

777

Earnings

-$0.84
-$0.67
-$0.49
-$0.32
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.